全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Drug Interaction between Sirolimus and Ranolazine in a Kidney Transplant Patient

DOI: 10.1155/2014/548243

Full-Text   Cite this paper   Add to My Lib

Abstract:

Purpose. The case of a kidney transplant recipient who experienced a probable drug interaction between sirolimus and ranolazine is reported. Summary. The narrow therapeutic window of immunosuppressive therapy in transplant recipients requires close monitoring for potential drug-drug interactions. The patient, a 57-year-old Caucasian male kidney transplant recipient, was stable for years on sirolimus as his primary immunosuppressive agent and had a history of chronic angina, for which he was prescribed ranolazine. Upon addition and dose escalation of ranolazine, whole blood sirolimus levels more than tripled, rising to immeasurably high concentrations. After holding sirolimus on multiple occasions and reducing dosage more than 50%, blood levels returned to therapeutic range, while continuing ranolazine. Conclusion. Since ranolazine is a documented P-GP and CYP3A inhibitor, and sirolimus a known substrate for both pathways, it is proposed that ranolazine inhibition of P-GP and CYP3A4 contributed to the significant elevation in sirolimus exposure. No alternative causes for the rise in sirolimus exposure were found, and assessment with the Drug Interaction Probability Scale finds this interaction to be probable. Clinicians should be aware of the potential for this interaction to cause elevated sirolimus exposure and subsequent increase in clinical effect or toxicity, in this case overimmunosuppression. 1. Introduction Immunosuppressive agents used in solid organ transplant have narrow therapeutic windows, making drug-drug interactions a major concern. As new drugs are brought to market, clinically significant drug interactions may be identified that have not been previously reported in the literature. This case report describes a possible drug interaction between sirolimus and ranolazine in a kidney transplant patient, leading to supratherapeutic blood concentrations of sirolimus. Ranolazine is a piperazine derivative approved for treatment of refractory angina; however, its exact mechanism of action is unclear. Ranolazine is metabolized primarily by intestinal and liver enzymes CYP3A (cytochrome P450, family 3A), and to a lesser extent CYP2D6, resulting in active metabolites, with less than 5% of compounds excreted in the urine. It is reported to be a mild inhibitor of CYP3A. Ranolazine is also a substrate and moderate inhibitor of p-glycoprotein (P-GP), an active transporter that serves as an intestinal efflux pump [1, 2]. The immunosuppressant sirolimus is a mammalian target of rapamycin (mTOR) inhibitor, which is used in transplant patients in place of,

References

[1]  Ranexa (Ranolazine) Package Insert, Gilead Sciences, Foster City, Calif, USA, 2011.
[2]  M. Jerling, “Clinical pharmacokinetics of ranolazine,” Clinical Pharmacokinetics, vol. 45, no. 5, pp. 469–491, 2006.
[3]  Rapamune (Sirolimus) Package Insert, Wyeth Pharmaceuticals, Philadelphia, Pa, USA, 2011.
[4]  D. A. Pierce and A. M. Reeves-Daniel, “Ranolazine-tacrolimus interaction,” Annals of Pharmacotherapy, vol. 44, no. 11, pp. 1844–1849, 2010.
[5]  H. Patni, M. Gitman, A. Hazzan, and K. D. Jhaveri, “Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient,” Renal Failure, vol. 34, no. 2, pp. 251–253, 2012.
[6]  A. C. Hylton and T. O. Ezekiel, “Rhabdomyolysis in a patient receiving ranolazine and simvastatin,” American Journal of Health-System Pharmacy, vol. 67, no. 21, pp. 1829–1831, 2010.
[7]  D. Capone, G. Palmiero, A. Gentile et al., “A pharmacokinetic interactions between clarithromycin and sirolimus in kidney transplant recipient,” Current Drug Metabolism, vol. 8, no. 4, pp. 379–381, 2007.
[8]  J. R. Horn, P. D. Hansten, and L. Chan, “Proposal for a new tool to evaluate drug interaction cases,” Annals of Pharmacotherapy, vol. 41, no. 4, pp. 674–680, 2007.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133